<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132779</url>
  </required_header>
  <id_info>
    <org_study_id>Intralipid</org_study_id>
    <nct_id>NCT03132779</nct_id>
  </id_info>
  <brief_title>Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion</brief_title>
  <official_title>Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Mohamed Bahaa Eldin Ahmed</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the effect of intralipid on the natural killer cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will done on women with recurrent spontaneous abortions having increased NKCELLS
      activity and evaluate the effect of Intralipid on them after re-estimation of NKcells
      activity again after one week of Intralipid adminstration
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2017</start_date>
  <completion_date type="Anticipated">February 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Women with unexplained recurrent spontaneous abortions having increased NKcells activity</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in NK cells activity after injection of intralipid</measure>
    <time_frame>One week</time_frame>
    <description>NK cells is measured before and after injection of intralipid and is noticed for change in activity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Recurrent Miscarriage</condition>
  <arm_group>
    <arm_group_label>One armed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group of patient will take Intralipid for all</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Adose of intralipid given and rechecking NKcells activity</description>
    <arm_group_label>One armed</arm_group_label>
    <other_name>Intralipid 18 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women icluded having recurrent spontaneous abortions equal or more than twice.

          -  Alittle women having increased NKCELLS activity.

        Exclusion Criteria:

          -  Any other diseases causing miscarriage as autoimmune (lupus erythematosus or
             antiphospholipid antibodies syndrome )or endocrinopathy (diabetes mellitus, thyroid
             disorders and hyperprolactinaemia)or thrombophilia (factor v leiden mutation, protein
             c or s deficiency, prothrombin G20210A mutation, antithrombin III deficiency ) or
             abnormal karyotyping to one or both of parents or previous history of hormonal
             contraception or intrauterine device usage at last 3 months or any contraindications
             for intralipid usage.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with recurrent spontaneous abortions</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan T Khairy, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Hassan Tawfik office</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sobhy R Mohammed, MBBCH</last_name>
    <phone>01003815460</phone>
    <phone_ext>002</phone_ext>
    <email>Garavandya@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed M BahaaEldin, MD</last_name>
    <phone>01111700556</phone>
    <phone_ext>002</phone_ext>
    <email>abaha0503@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Bahaa Eldin Ahmed</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Intralipid</keyword>
  <keyword>NK cells</keyword>
  <keyword>Recurrent miscarriage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

